Clinical Trial Results:
A randomized, multicenter, double-blind phase 3 study of SAR439859 plus palbociclib versus letrozole plus palbociclib for the treatment of patients with ER (+), HER2 (-) breast cancer who have not received prior systemic anti-cancer treatment for advanced disease
Summary
|
|
EudraCT number |
2020-001824-33 |
Trial protocol |
FR GB NL PT HU BE PL FI CZ AT BG IT |
Global completion date |
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
21 Dec 2023
|
First version publication date |
21 Dec 2023
|
Other versions |
|
Summary report(s) |
EFC15935 EU RESULTS SUMMARY |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.